Hagens Berman, an investor-rights law firm, today announced that it is investigating Abiomed, Inc. (NASDAQ:ABMD) (“Abiomed”) for potential violations of the securities laws following the disclosure of a Department of Justice probe into the marketing and labeling of its flagship product, the Impella 2.5 system.
Firefox recommends the PDF Plugin for Mac OS X for viewing PDF documents in your browser.
We can also show you Legal Updates using the Google Viewer; however, you will need to be logged into Google Docs to view them.
Please choose one of the above to proceed!
LOADING PDF: If there are any problems, click here to download the file.
Topics: Dodd-Frank, DOJ, Labeling, Marketing, Whistleblowers
Published In: Securities Updates
DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
© Steve Berman, Hagens Berman | Attorney Advertising